

Botulinum Toxins Market by Product (Botox, Dysport, Jeuveau, Myobloc), Application (Cosmetic (Wrinkle Removal, Contouring, Skin rejuvenation), Therapeutic (OAB, Migraine, Spasm, Pain)), Volume, End User (Clinics, Center), Region - Global Forecast to 2030

<https://marketpublishers.com/r/B76D1274800BEN.html>

Date: July 2025

Pages: 236

Price: US\$ 4,950.00 (Single User License)

ID: B76D1274800BEN

Abstracts

The global botulinum toxins market is projected to reach USD 15.7 billion by 2030 from USD 8.9 billion in 2025, at a CAGR of 11.7% during the forecast period.

The growth of the market can be attributed to the increasing societal and occupational emphasis on looking youthful, especially in urban and professional environments. This trend encourages more individuals to seek cosmetic procedures, including the use of botulinum toxins. In developing countries, rising disposable incomes and exposure to urban lifestyles are creating new patient demographics, which significantly increases the demand for botulinum toxins. These factors are expected to drive the market for botulinum toxins during the forecast period.

“Based on product, Botox held the largest share of the botulinum toxins market in 2024.”

The botulinum toxins market is divided by product into major brands, including Botox, Dysport, Jeuveau, Myobloc, Xeomin, and other products. In 2024, Botox held the largest share of the market. The brand has established a strong reputation for clinical reliability, which instills confidence among cosmetologists, dermatologists, and aestheticians, as well as trust from end users such as clinics, spas, and hospitals. Botox offers a wide range of applications and demonstrates a safe and effective profile compared to its competitors.

Botox is utilized in various medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its increasing demand. Additionally, Botox provides extensive training modules and patient support programs. These factors have enabled Botox to surpass its competitors and secure a leading position in the botulinum toxins market.

“Based on type, the type A botulinum toxins segment held the largest share of the market in 2024.”

The botulinum toxins market is divided into two main categories based on type: type A and type B botulinum toxins. Type A botulinum toxins occupy a significant share of the global market, primarily due to their proven clinical effectiveness and long history of regulatory approvals. Being the first serotype in this category, type A is supported by substantial evidence demonstrating its safety and efficacy in both therapeutic and aesthetic applications.

Type A is authorized for a wide range of uses around the world, including treatments for chronic migraines, spasticity, and reducing facial wrinkles, which contributes to its widespread adoption. Additionally, type A offers a longer-lasting effect, typically lasting between three and six months, resulting in fewer treatment sessions and greater patient convenience.

These factors reinforce type A's dominant position in manufacturing, sales, and demand within the botulinum toxins industry. In comparison, type A is preferred over type B because it provides effects lasting longer (up to six months) and has more extensive regulatory approvals for aesthetic and therapeutic purposes. It is also more potent at smaller doses and less likely to develop antibody resistance. Furthermore, type A is widely recognized among physicians, supported by extensive clinical experience and research, which cements its leading market position globally.

“Based on applications, the aesthetics segment commanded the largest market share in 2024.”

The aesthetics segment, particularly wrinkle removal, is expected to dominate the botulinum toxins market. In 2024, wrinkle removal continues to be a popular and well-recognized application of botulinum toxins, especially among adults seeking non-surgical anti-aging solutions. Clinics report high patient volumes, primarily for the treatment of forehead lines, crow's feet, and glabellar (frown) lines. This popularity is attributed to the visible and relatively quick results, along with fewer treatment cycles

needed, making it widely accepted across diverse demographics. The procedure duration is short, and the results are noticeable quickly, leading to its prominence among non-surgical options.

“Based on end users, the dermatology clinics & hospitals segment accounted for the largest share in 2024.”

The global botulinum toxins market is segmented by end user into dermatology clinics & hospitals, beauty centers, medical spas, and other end users. In 2024, dermatology clinics & hospitals witnessed a significant demand for botulinum toxin products, as they serve as primary providers for both aesthetic and medical procedures.

Dermatology clinics primarily focus on cosmetic treatments, such as wrinkle reduction and facial contouring, which are among the most common applications of botulinum toxins. In contrast, hospitals use these toxins to treat various medical conditions, including muscle spasticity, chronic migraines, and dystonia. With their well-equipped facilities, access to trained professionals, and capacity to manage both routine and complex cases, hospitals and clinics are key players that drive consistent usage of botulinum toxin products.

“The market in North America is expected to hold a significant market share for botulinum toxins throughout the forecast period.”

The botulinum toxins market comprises five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North America region held a significant market share for botulinum toxins. This growth is primarily attributed to a strong healthcare infrastructure and the considerable disposable income of the population. North America is also home to several major manufacturers of botulinum toxins, fostering a sustainable ecosystem of buyers, distributors, and suppliers. These factors are anticipated to contribute to the growth of the botulinum toxins market in North America.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)

By Designation: C-level Executives (35%), Directors (25%), and Others (40%)

By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)

The key players profiled in the botulinum toxins market are by AbbVie Inc. (US), Ipsen Biopharmaceuticals Inc. (France), Galderma (Switzerland), Hugel, Inc. (South Korea), Revance Therapeutics, Inc. (US), Evolus, Inc. (US), Medytox, Inc. (South Korea), Merz Pharmaceuticals GmbH (Germany), Supernus Pharmaceuticals, Inc. (US), Daewoong Pharmaceutical Co., Ltd. (South Korea), Huons Co., Ltd. (South Korea), Eisai Co., Ltd. (Japan) and Hugh Source (International) Ltd. (Hong Kong).

Research Coverage

The research report examines the botulinum toxins market by product, type, application, end user, and region. This research examines the factors contributing to market expansion, analyzes the challenges and opportunities currently faced by various industries, and provides details on the competitive landscape, including both market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.

Reasons to Buy the Report

The report will assist market leaders and new entrants by providing accurate revenue estimates for the overall botulinum toxins market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following points:

Market Penetration: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.

Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.

Market Development: Insightful data on profitable developing areas.

Market Diversification: Details about recent developments and advancements in the botulinum toxins market.

Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY RESEARCH
 - 2.1.1.1 Key secondary sources
 - 2.1.1.2 Key data from secondary sources
 - 2.1.1.3 Objectives of secondary research
 - 2.1.2 PRIMARY RESEARCH
 - 2.1.2.1 Key primary sources
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 BOTTOM-UP APPROACH
 - 2.2.1.1 Company revenue estimation
 - 2.2.1.2 Customer-based market estimation
 - 2.2.1.3 Primary interviews
 - 2.2.2 TOP-DOWN APPROACH
- 2.3 GROWTH RATE ASSUMPTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 BOTULINUM TOXINS MARKET OVERVIEW

Botulinum Toxins Market by Product (Botox, Dysport, Jeuveau, Myobloc), Application (Cosmetic (Wrinkle Removal),...

4.2 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION AND COUNTRY, 2024 (USD MILLION)

4.3 BOTULINUM TOXINS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)

4.4 BOTULINUM TOXINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increased adoption in therapeutic indications

5.2.1.2 Reduced out-of-pocket expenditure due to sufficient reimbursement schemes

5.2.1.3 Aesthetic consciousness among adults

5.2.1.4 Greater acceptance and normalization of botulinum toxins among millennials and Gen Z

5.2.2 RESTRAINTS

5.2.2.1 Risk of infection and safety concerns

5.2.2.2 Complex regulatory framework and compliance standards

5.2.3 OPPORTUNITIES

5.2.3.1 High growth opportunities in emerging economies

5.2.3.2 Formulation advancements and innovations for improved safety

5.2.4 CHALLENGES

5.2.4.1 High treatment costs

5.2.4.2 Social and cultural barriers

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022–2024

5.4.2 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION, 2022–2024

5.5 VALUE CHAIN ANALYSIS

5.5.1 RESEARCH & DEVELOPMENT

5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING

5.5.3 DISTRIBUTION AND MARKETING & SALES

5.5.4 AFTER-SALES SERVICES

5.6 SUPPLY CHAIN ANALYSIS

5.6.1 PROMINENT COMPANIES

5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES

- 5.6.3 END USERS
- 5.7 ECOSYSTEM ANALYSIS
 - 5.7.1 ROLE IN ECOSYSTEM
- 5.8 INVESTMENT & FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
 - 5.9.1 KEY TECHNOLOGIES
 - 5.9.1.1 Jet-based delivery systems
 - 5.9.1.2 Facial imaging and mapping systems
 - 5.9.2 COMPLEMENTARY TECHNOLOGIES
 - 5.9.2.1 Laser, RF, & ultrasound-based devices
 - 5.9.3 ADJACENT TECHNOLOGIES
 - 5.9.3.1 3D imaging and AI-based facial mapping
- 5.10 PATENT ANALYSIS
 - 5.10.1 INNOVATIONS AND PATENT REGISTRATIONS
- 5.11 TRADE ANALYSIS
 - 5.11.1 IMPORT DATA FOR HS CODE 300290, 2020–2024
 - 5.11.2 EXPORT DATA FOR HS CODE 300290, 2020–2024
- 5.12 KEY CONFERENCES & EVENTS, 2025–2026
- 5.13 CASE STUDY ANALYSIS
 - 5.13.1 COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES
 - 5.13.2 DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP EFFECIENTLY MEET CUSTOMER DEMANDS
 - 5.13.3 COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES
- 5.14 REGULATORY ANANLYSIS
 - 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - 5.14.2 KEY REGULATORY GUIDELINES
 - 5.14.2.1 North America
 - 5.14.2.1.1 US
 - 5.14.2.1.2 Canada
 - 5.14.2.2 Europe
 - 5.14.2.2.1 UK
 - 5.14.2.2.2 France
 - 5.14.2.2.3 Germany
 - 5.14.2.3 Asia Pacific
 - 5.14.2.3.1 China
 - 5.14.2.3.2 Japan

- 5.14.2.3.3 India
- 5.14.2.4 Latin America
 - 5.14.2.4.1 Brazil
- 5.14.2.5 Middle East & Africa
 - 5.14.2.5.1 UAE
- 5.14.3 REGULATORY STANDARDS/APPROVALS
- 5.15 REIMBURSEMENT SCENARIO ANALYSIS
 - 5.15.1 NORTH AMERICA
 - 5.15.1.1 US
 - 5.15.1.2 Canada
 - 5.15.2 EUROPE
 - 5.15.2.1 UK
 - 5.15.2.2 Germany
 - 5.15.2.3 France
 - 5.15.2.4 Italy
 - 5.15.2.5 Spain
 - 5.15.3 ASIA PACIFIC
 - 5.15.3.1 China
 - 5.15.3.2 Japan
 - 5.15.3.3 India
 - 5.15.3.4 Australia
 - 5.15.4 LATIN AMERICA
 - 5.15.4.1 Brazil
 - 5.15.4.2 Mexico
 - 5.15.5 MIDDLE EAST & AFRICA
 - 5.15.5.1 GCC Countries
 - 5.15.5.2 Africa (Major Economies)
- 5.16 PORTER'S FIVE FORCE ANALYSIS
 - 5.16.1 THREAT OF NEW ENTRANTS
 - 5.16.2 THREAT OF SUBSTITUTES
 - 5.16.3 BARGAINING POWER OF SUPPLIERS
 - 5.16.4 BARGAINING POWER OF BUYERS
 - 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.17 KEY STAKEHOLDERS & BUYING CRITERIA
 - 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
 - 5.17.2 BUYING CRITERIA
- 5.18 UNMET NEEDS
- 5.19 IMPACT OF 2025 US TARIFF ON BOTULINUM TOXINS MARKET
 - 5.19.1 INTRODUCTION

5.19.2 KEY TARIFF RATES

5.19.3 PRICE IMPACT ANALYSIS

5.19.4 IMPACT ON COUNTRY/REGION

5.19.4.1 North America

5.19.4.1.1 US

5.19.4.2 Europe

5.19.4.3 Asia Pacific

5.19.5 IMPACT ON END-USE INDUSTRIES

5.20 IMPACT OF AI/GEN AI ON BOTULINUM TOXINS MARKET

5.20.1 MARKET POTENTIAL OF AI/GEN AI

5.20.2 AI USE CASES

5.20.3 KEY COMPANIES IMPLEMENTING AI/GEN AI

5.20.4 FUTURE OF AI/GEN AI

6 BOTULINUM TOXINS MARKET, BY PRODUCT

6.1 INTRODUCTION

6.2 BOTOX

6.2.1 USE IN THERAPEUTIC AND COSMETIC PROCEDURES TO AUGMENT MARKET GROWTH

6.3 DYSPORT

6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT TO BOOST MARKET ADOPTION

6.4 JEUVEAU

6.4.1 INTRODUCTION OF TECH-ENABLED PLATFORMS FOR CONSUMER SUPPORT TO FUEL MARKET GROWTH

6.5 MYOBLOC

6.5.1 WIDE THERAPEUTIC PROFILE TO DRIVE MARKET

6.6 XEOMIN

6.6.1 STABLE THERAPEUTIC PERFORMANCE AND EFFECTIVE FORMULATION TO FAVOR MARKET GROWTH

6.7 OTHER PRODUCTS

7 BOTULINUM TOXINS MARKET, BY TYPE

7.1 INTRODUCTION

7.2 TYPE A BOTULINUM TOXINS

7.2.1 GLOBAL CLINICAL ACCEPTANCE AND PROVEN EFFICACY TO SUPPORT MARKET GROWTH

7.3 TYPE B BOTULINUM TOXINS

7.3.1 WIDE THERAPEUTIC UTILITY AND DISTINCT CLINICAL PROFILE TO PROPEL MARKET GROWTH

8 BOTULINUM TOXINS MARKET, BY AGE GROUP

8.1 INTRODUCTION

8.2 17 YEARS OR YOUNGER

8.2.1 INCREASING THERAPEUTIC USE OF BOTOX TO PROPEL MARKET GROWTH AMONG YOUNGER PEOPLE

8.3 18–34 YEARS

8.3.1 GOOD TOLERABILITY AND IMPROVED PATIENT-REPORTED OUTCOMES TO DRIVE ADOPTION OF BOTOX TREATMENT

8.4 35–50 YEARS

8.4.1 NEED FOR APPEARANCE MAINTENANCE AND BETTER SOCIAL ENGAGEMENT TO FUEL MARKET GROWTH

8.5 51–64 YEARS OLD

8.5.1 SUSTAINED DEMAND FOR COSMETIC AND THERAPEUTIC INDICATIONS TO AUGMENT MARKET GROWTH

8.6 65 YEARS OR OLDER

8.6.1 HIGH DEMAND FOR FUNCTIONAL IMPROVEMENTS AND CONSERVATIVE AESTHETIC ENHANCEMENTS TO DRIVE MARKET

9 BOTULINUM TOXINS MARKET, BY APPLICATION

9.1 INTRODUCTION

9.2 COSMETIC APPLICATIONS

9.2.1 WRINKLE REMOVAL

9.2.1.1 Surge in beauty clinics and medical spas to support segment growth

9.2.2 FACIAL CONTOURING

9.2.2.1 Rising desire for natural results and growing appeal of minimally invasive procedures to propel segment growth

9.2.3 SKIN REJUVENATION

9.2.3.1 Increased adoption of minimally invasive facial enhancement procedures to boost market growth

9.3 THERAPEUTIC APPLICATIONS

9.3.1 PAIN MANAGEMENT

9.3.1.1 Rising need for pain management techniques to drive segment

9.3.2 OVERACTIVE BLADDER

9.3.2.1 Localized mechanism, strong efficacy, and long-lasting relief to spur demand for botulinum toxins among neurogenic patients

9.4 OTHER APPLICATIONS

10 BOTULINUM TOXINS MARKET, BY END USER

10.1 INTRODUCTION

10.2 DERMATOLOGY CLINICS & HOSPITALS

10.2.1 RISING TREND OF MEDICAL TOURISM AND INCREASING POPULARITY OF PLASTIC SURGERY TO SUPPORT MARKET GROWTH

10.3 BEAUTY CENTERS

10.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENTS TO BOOST MARKET GROWTH

10.4 MEDICAL SPAS

10.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST EFFECTIVENESS TO SPUR MARKET GROWTH

10.5 OTHER END USERS

11 BOTULINUM TOXINS MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

11.2.2 US

11.2.2.1 US to dominate North American botulinum toxins market during study period

11.2.3 CANADA

11.2.3.1 Preference for minimally invasive cosmetic procedures among aging individuals to drive market growth

11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

11.3.2 GERMANY

11.3.2.1 Selective reimbursement regimes and large number of cosmetic procedures to spur market demand

11.3.3 UK

11.3.3.1 Increased demand for Botox for cosmetic enhancements to propel market growth

11.3.4 FRANCE

11.3.4.1 Increased awareness and broader societal acceptance of cosmetic treatments to augment market growth

11.3.5 ITALY

11.3.5.1 Rising number of medical aesthetic procedures to aid market growth

11.3.6 SPAIN

11.3.6.1 Growing availability of safe and effective minimally invasive or non-invasive aesthetic treatments to aid market growth

11.3.7 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

11.4.2 JAPAN

11.4.2.1 Popularity of medical tourism to increase demand for cosmetic treatments

11.4.3 CHINA

11.4.3.1 Surging demand for non-surgical aesthetic procedures to support market growth

11.4.4 INDIA

11.4.4.1 Lack of reimbursements for aesthetic treatments alongside social and ethical concerns to limit market growth

11.4.5 AUSTRALIA

11.4.5.1 Increased number of aesthetic procedures to grow market for botulinum toxins

11.4.6 SOUTH KOREA

11.4.6.1 Rising availability of safe and effective minimally invasive and non-invasive aesthetic procedures and products to drive market

11.4.7 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.5.2 BRAZIL

11.5.2.1 Rapid growth in medical tourism and high disposable incomes to expedite market growth

11.5.3 MEXICO

11.5.3.1 Rising influx of medical tourists from US to drive adoption of cost-effective cosmetic procedures

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST & AFRICA

11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11.6.2 GCC COUNTRIES

11.6.2.1 Favorable government policies to propel market growth

11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY PLAYERS' STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET

12.3 REVENUE ANALYSIS, 2020–2024

12.4 MARKET SHARE ANALYSIS, 2024

12.4.1 MARKET RANKING OF KEY PLAYERS, 2024

12.5 COMPANY VALUATION & FINANCIAL METRICS

12.5.1 FINANCIAL METRICS

12.5.2 COMPANY VALUATION

12.6 BRAND/PRODUCT COMPARISON

12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

12.7.1 STARS

12.7.2 PERVASIVE PLAYERS

12.7.3 EMERGING LEADERS

12.7.4 PARTICIPANTS

12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

12.7.5.1 Company footprint

12.7.5.2 Region footprint

12.7.5.3 Type footprint

12.7.5.4 Application footprint

12.7.5.5 End-user footprint

12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

12.8.1 PROGRESSIVE COMPANIES

12.8.2 RESPONSIVE COMPANIES

12.8.3 DYNAMIC COMPANIES

12.8.4 STARTING BLOCKS

12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024

12.8.5.1 Detailed list of key startups/SMEs

12.8.5.2 Competitive benchmarking of key startups/SMEs

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES & APPROVALS

12.9.2 DEALS

12.9.3 EXPANSIONS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 ABBVIE INC.

- 13.1.1.1 Business overview
- 13.1.1.2 Products offered
- 13.1.1.3 Recent developments
 - 13.1.1.3.1 Deals
 - 13.1.1.3.2 Expansions
 - 13.1.1.3.3 Other developments
- 13.1.1.4 MnM view
 - 13.1.1.4.1 Key strengths
 - 13.1.1.4.2 Strategic choices
 - 13.1.1.4.3 Weaknesses & competitive threats

13.1.2 IPSEN BIOPHARMACEUTICALS, INC.

- 13.1.2.1 Business overview
- 13.1.2.2 Products offered
- 13.1.2.3 Recent developments
 - 13.1.2.3.1 Product approvals
 - 13.1.2.3.2 Expansions
 - 13.1.2.3.3 Other developments
- 13.1.2.4 MnM view
 - 13.1.2.4.1 Key strengths
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses & competitive threats

13.1.3 GALDERMA

- 13.1.3.1 Business overview
- 13.1.3.2 Products offered
- 13.1.3.3 Recent developments
 - 13.1.3.3.1 Product launches
 - 13.1.3.3.2 Deals
 - 13.1.3.3.3 Expansions
- 13.1.3.4 MnM view
 - 13.1.3.4.1 Key strengths
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses & competitive threats

13.1.4 HUGEL, INC.

- 13.1.4.1 Business overview
- 13.1.4.2 Products offered
- 13.1.4.3 Recent developments
 - 13.1.4.3.1 Product approvals
 - 13.1.4.3.2 Deals

- 13.1.4.3.3 Expansions
- 13.1.4.4 MnM view
 - 13.1.4.4.1 Key strengths
 - 13.1.4.4.2 Strategic choices
 - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 REVANCE
 - 13.1.5.1 Business overview
 - 13.1.5.2 Products offered
 - 13.1.5.3 Recent developments
 - 13.1.5.3.1 Product launches & approvals
 - 13.1.5.3.2 Deals
 - 13.1.5.4 MnM view
 - 13.1.5.4.1 Key strengths
 - 13.1.5.4.2 Strategic choices
 - 13.1.5.4.3 Weaknesses & competitive threats
- 13.1.6 EVOLUS, INC.
 - 13.1.6.1 Business overview
 - 13.1.6.2 Products offered
 - 13.1.6.3 Recent developments
 - 13.1.6.3.1 Product launches & approvals
 - 13.1.6.3.2 Deals
- 13.1.7 MEDYTOX
 - 13.1.7.1 Business overview
 - 13.1.7.2 Products offered
 - 13.1.7.3 Recent developments
 - 13.1.7.3.1 Product approvals
 - 13.1.7.3.2 Deals
- 13.1.8 MERZ PHARMA
 - 13.1.8.1 Business overview
 - 13.1.8.2 Products offered
 - 13.1.8.3 Recent developments
 - 13.1.8.3.1 Product approvals
- 13.1.9 SUPERNUS PHARMACEUTICALS, INC.
 - 13.1.9.1 Business overview
 - 13.1.9.2 Products offered
- 13.1.10 DAEWOONG PHARMACEUTICAL CO., LTD.
 - 13.1.10.1 Business overview
 - 13.1.10.2 Products offered
 - 13.1.10.3 Recent developments

- 13.1.10.3.1 Product launches & approvals
- 13.1.11 HUONS
 - 13.1.11.1 Business overview
 - 13.1.11.2 Products offered
 - 13.1.11.3 Recent developments
 - 13.1.11.3.1 Product launches & approvals
- 13.1.12 EISAI CO., LTD.
 - 13.1.12.1 Business overview
 - 13.1.12.2 Products offered
- 13.1.13 HUGH SOURCE (INTERNATIONAL) LTD.
 - 13.1.13.1 Business overview
 - 13.1.13.2 Products offered
- 13.2 OTHER PLAYERS
 - 13.2.1 DERMAX CO., LTD.
 - 13.2.2 GUFIC BIOSCIENCES
 - 13.2.3 OCEAN PHARMACEUTICAL
 - 13.2.4 CROMA-PHARMA GMBH
 - 13.2.5 MICROGEN
 - 13.2.6 JDBIO CO., LTD.
 - 13.2.7 CKD BIO
 - 13.2.8 ATRAZIST ARAY CO.
 - 13.2.9 GUANGZHOU AOMA BUSINESS CO., LTD.
 - 13.2.10 JETEMA CO., LTD.
 - 13.2.11 SINOPHARM GROUP CO., LTD.
 - 13.2.12 QUFU HANTANG BIOTECHNOLOGY CO., LTD.

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 BOTULINUM TOXINS MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2 BOTULINUM TOXINS MARKET: STUDY ASSUMPTIONS

TABLE 3 BOTULINUM TOXINS MARKET: RISK ANALYSIS

TABLE 4 BOTULINUM TOXINS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 5 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022–2024 (USD)

TABLE 6 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION, 2022–2024 (USD THOUSAND)

TABLE 7 BOTULINUM TOXINS MARKET: ROLE IN ECOSYSTEM

TABLE 8 BOTULINUM TOXINS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024

TABLE 9 IMPORT SCENARIO FOR HS CODE 300290, BY COUNTRY, 2020–2024 (USD)

TABLE 10 EXPORT SCENARIO FOR HS CODE 300290, BY COUNTRY, 2020–2024 (USD)

TABLE 11 BOTULINUM TOXINS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026

TABLE 12 CASE STUDY 1: COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES

TABLE 13 CASE STUDY 2: DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP EFFICIENTLY MEET CUSTOMER DEMANDS

TABLE 14 CASE STUDY 3: COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES

TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 19 REGULATORY STANDARD/APPROVAL AUTHORIZATION AND CLASS OF APPROVAL FOR PRODUCTS USED IN AESTHETIC PROCEDURES, BY COUNTRY

TABLE 20 BOTULINUM TOXINS MARKET: PORTER'S FIVE FORCES

TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY TYPE

TABLE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY END USER

TABLE 23 BOTULINUM TOXINS MARKET: UNMET NEEDS

TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024

TABLE 25 KEY COMPANIES IMPLEMENTING AI/GEN AI IN BOTULINUM TOXINS MARKET

TABLE 26 BOTULINUM TOXINS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 27 BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 28 TYPE A BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 29 NORTH AMERICA: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30 EUROPE: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 31 ASIA PACIFIC: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 LATIN AMERICA: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: TYPE A BOTULINUM TOXINS MARKET, 2023–2030 (USD MILLION)

TABLE 34 TYPE A BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 35 TYPE A BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 36 TYPE B BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 37 NORTH AMERICA: TYPE B BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 38 TYPE B BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 39 TYPE B BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 40 BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 41 BOTULINUM TOXINS MARKET FOR 17 YEARS OR YOUNGER, BY REGION, 2023–2030 (USD MILLION)

TABLE 42 BOTULINUM TOXINS MARKET FOR 18–34 YEARS, BY REGION, 2023–2030 (USD MILLION)

TABLE 43 BOTULINUM TOXINS MARKET FOR 35–50 YEARS, BY REGION, 2023–2030 (USD MILLION)

TABLE 44 BOTULINUM TOXINS MARKET FOR 51–64 YEARS, BY REGION, 2023–2030 (USD MILLION)

TABLE 45 BOTULINUM TOXINS MARKET FOR 65 YEARS OR OLDER, BY REGION, 2023–2030 (USD MILLION)

TABLE 46 BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 47 BOTULINUM TOXINS MARKET FOR COSMETIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 48 BOTULINUM TOXINS MARKET FOR COSMETIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 49 WRINKLE REMOVAL MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 50 FACIAL CONTOURING MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 51 SKIN REJUVENATION MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 52 BOTULINUM TOXINS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 53 BOTULINUM TOXINS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 54 PAIN MANAGEMENT MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 55 PAIN MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 56 OVERACTIVE BLADDER MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 57 BOTULINUM TOXINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 58 BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 59 BOTULINUM TOXINS MARKET FOR DERMATOLOGY CLINICS & HOSPITALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 60 BOTULINUM TOXINS MARKET FOR BEAUTY CENTERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 61 BOTULINUM TOXINS MARKET FOR MEDICAL SPAS, BY REGION, 2023–2030 (USD MILLION)

TABLE 62 BOTULINUM TOXINS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 63 BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 64 GLOBAL: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023

(UNITS)

TABLE 65 NORTH AMERICA: KEY MACROINDICATORS

TABLE 66 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 67 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 68 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 69 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 70 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 71 US: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 72 US: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 73 CANADA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 74 EUROPE: BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 75 EUROPE: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 76 EUROPE: BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 77 EUROPE: BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 78 EUROPE: BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 79 EUROPE: KEY MACROINDICATORS

TABLE 80 GERMANY: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 81 GERMANY: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 82 UK: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 83 UK: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 84 FRANCE: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 85 FRANCE: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 86 ITALY: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 87 ITALY: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 88 SPAIN: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 89 SPAIN: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 90 REST OF EUROPE: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 91 ASIA PACIFIC: KEY MACROINDICATORS

TABLE 92 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 94 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 95 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 96 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 97 JAPAN: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 98 CHINA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 99 INDIA: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 100 INDIA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 101 AUSTRALIA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 102 SOUTH KOREA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 103 REST OF ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 104 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 106 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 107 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 108 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 109 LATIN AMERICA: KEY MACROINDICATORS

TABLE 110 BRAZIL: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 111 BRAZIL: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 112 MEXICO: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS)

TABLE 113 MEXICO: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 114 REST OF LATIN AMERICA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 115 MIDDLE EAST & AFRICA: KEY MACROINDICATORS

TABLE 116 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 117 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 118 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION)

TABLE 119 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 120 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 121 GCC COUNTRIES: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 122 REST OF MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET, 2022–2025

TABLE 124 BOTULINUM TOXINS MARKET: DEGREE OF COMPETITION

TABLE 125 BOTULINUM TOXINS MARKET: REGION FOOTPRINT

TABLE 126 BOTULINUM TOXINS MARKET: TYPE FOOTPRINT

TABLE 127 BOTULINUM TOXINS MARKET: APPLICATION FOOTPRINT

TABLE 128 BOTULINUM TOXINS MARKET: END-USER FOOTPRINT

TABLE 129 BOTULINUM TOXINS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS

TABLE 130 BOTULINUM TOXINS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION

TABLE 131 BOTULINUM TOXINS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025

TABLE 132 BOTULINUM TOXINS MARKET: DEALS, JANUARY 2022–JUNE 2025

TABLE 133 BOTULINUM TOXINS MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025

TABLE 134 ABBVIE INC.: COMPANY OVERVIEW

TABLE 135 ABBVIE INC.: PRODUCTS OFFERED

TABLE 136 ABBVIE INC.: DEALS, JANUARY 2022–JUNE 2025

TABLE 137 ABBVIE INC.: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 138 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025

TABLE 139 IPSEN BIOPHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 140 IPSEN BIOPHARMACEUTICALS, INC.: PRODUCTS OFFERED

TABLE 141 IPSEN BIOPHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025

TABLE 142 IPSEN BIOPHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 143 IPSEN BIOPHARMACEUTICALS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025

TABLE 144 GALDERMA: COMPANY OVERVIEW

TABLE 145 GALDERMA: PRODUCTS OFFERED

TABLE 146 GALDERMA: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025

TABLE 147 GALDERMA: DEALS, JANUARY 2022–JUNE 2025

TABLE 148 GALDERMA: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 149 HUGEL, INC.: COMPANY OVERVIEW

TABLE 150 HUGEL, INC.: PRODUCTS OFFERED

TABLE 151 HUGEL, INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025

TABLE 152 HUGEL, INC.: DEALS, JANUARY 2022–JUNE 2025

TABLE 153 HUGEL, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025

TABLE 154 REVANCE: COMPANY OVERVIEW

TABLE 155 REVANCE: PRODUCTS OFFERED

TABLE 156 REVANCE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025

TABLE 157 REVANCE: DEALS, JANUARY 2022–JUNE 2025

TABLE 158 EVOLUS, INC.: COMPANY OVERVIEW

TABLE 159 EVOLUS, INC.: PRODUCTS OFFERED

TABLE 160 EVOLUS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025

TABLE 161 EVOLUS, INC.: DEALS, JANUARY 2022–JUNE 2025

TABLE 162 MEDYTOX: COMPANY OVERVIEW

TABLE 163 MEDYTOX: PRODUCTS OFFERED

TABLE 164 MEDYTOX: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025

TABLE 165 MEDYTOX: DEALS, JANUARY 2022–JUNE 2025

TABLE 166 MERZ PHARMA: COMPANY OVERVIEW

TABLE 167 MERZ PHARMA: PRODUCTS OFFERED

TABLE 168 MERZ PHARMA: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025

TABLE 169 SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 170 SUPERNUS PHARMACEUTICALS, INC.: PRODUCTS OFFERED

TABLE 171 DAEWOONG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW

TABLE 172 DAEWOONG PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED

TABLE 173 DAEWOONG PHARMACEUTICAL CO., LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025

TABLE 174 HUONS: COMPANY OVERVIEW

TABLE 175 HUONS: PRODUCTS OFFERED

TABLE 176 HUONS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025

TABLE 177 EISAI CO., LTD.: COMPANY OVERVIEW

TABLE 178 EISAI CO., LTD.: PRODUCTS OFFERED

TABLE 179 HUGH SOURCE (INTERNATIONAL) LTD.: COMPANY OVERVIEW

TABLE 180 HUGH SOURCE (INTERNATIONAL) LTD.: PRODUCTS OFFERED

TABLE 181 DERMAX CO., LTD.: COMPANY OVERVIEW

TABLE 182 GUFIC BIOSCIENCES: COMPANY OVERVIEW

TABLE 183 OCEAN PHARMACEUTICAL: COMPANY OVERVIEW

TABLE 184 CROMA-PHARMA GMBH: COMPANY OVERVIEW

TABLE 185 MICROGEN: COMPANY OVERVIEW

TABLE 186 JDBIO CO., LTD.: COMPANY OVERVIEW

TABLE 187 CKD BIO: COMPANY OVERVIEW

TABLE 188 ATRAZIST ARAY CO.: COMPANY OVERVIEW

TABLE 189 GUANGZHOU AOMA BUSINESS CO., LTD.: COMPANY OVERVIEW

TABLE 190 JETEMA CO., LTD.: COMPANY OVERVIEW

TABLE 191 SINOPHARM GROUP CO., LTD.: COMPANY OVERVIEW

TABLE 192 QUFU HANTANG BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW

List Of Figures

LIST OF FIGURES

FIGURE 1 BOTULINUM TOXINS MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 BOTULINUM TOXINS MARKET: YEARS CONSIDERED

FIGURE 3 BOTULINUM TOXINS MARKET: RESEARCH DATA

FIGURE 4 BOTULINUM TOXINS MARKET: RESEARCH DESIGN

FIGURE 5 BOTULINUM TOXINS MARKET: KEY SECONDARY SOURCES

FIGURE 6 BOTULINUM TOXINS MARKET: KEY DATA FROM SECONDARY SOURCES

FIGURE 7 BOTULINUM TOXINS MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)

FIGURE 8 BOTULINUM TOXINS MARKET: KEY SUPPLY- AND DEMAND-SIDE PARTICIPANTS

FIGURE 9 BOTULINUM TOXINS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (BY COMPANY TYPE, DESIGNATION, AND REGION)

FIGURE 10 BOTULINUM TOXINS MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS

FIGURE 11 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

FIGURE 12 BOTULINUM TOXINS MARKET: COMPANY REVENUE ESTIMATION

FIGURE 13 BOTULINUM TOXINS MARKET: END USER- AND REVENUE-MAPPING-BASED MARKET SIZE ESTIMATION METHODOLOGY

FIGURE 14 BOTULINUM TOXINS MARKET: TOP-DOWN APPROACH

FIGURE 15 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS

FIGURE 16 BOTULINUM TOXINS MARKET: DATA TRIANGULATION METHODOLOGY

FIGURE 17 BOTULINUM TOXINS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)

FIGURE 18 BOTULINUM TOXINS MARKET, BY AGE GROUP, 2025 VS. 2030 (USD MILLION)

FIGURE 19 BOTULINUM TOXINS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 20 BOTULINUM TOXINS MARKET: REGIONAL SNAPSHOT

FIGURE 21 INCREASED AESTHETIC CONSCIOUSNESS AND HIGH DISPOSABLE INCOME TO DRIVE MARKET

FIGURE 22 JAPAN AND THERAPEUTIC APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2024

FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES

DURING STUDY PERIOD

FIGURE 24 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030

FIGURE 25 BOTULINUM TOXINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 26 BOTULINUM TOXINS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

FIGURE 27 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022–2024 (USD)

FIGURE 28 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION, 2022–2024 (USD)

FIGURE 29 BOTULINUM TOXINS MARKET: VALUE CHAIN ANALYSIS

FIGURE 30 BOTULINUM TOXINS MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 31 BOTULINUM TOXINS MARKET: ECOSYSTEM ANALYSIS

FIGURE 32 BOTULINUM TOXINS MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 (USD MILLION)

FIGURE 33 NUMBER OF DEALS IN BOTULINUM TOXINS MARKET, BY KEY PLAYER, 2019–2023

FIGURE 34 VALUE OF DEALS IN BOTULINUM TOXINS MARKET, BY KEY PLAYER, 2019–2023 (USD)

FIGURE 35 BOTULINUM TOXINS MARKET: TOP COMPANIES/APPLICANTS FOR BOTULINUM TOXIN PATENTS AND NUMBER OF PATENTS GRANTED, 2015–2025

FIGURE 36 BOTULINUM TOXINS MARKET: IMPORT SCENARIO FOR HS CODE 300290, 2020–2024 (USD)

FIGURE 37 BOTULINUM TOXINS MARKET: EXPORT SCENARIO FOR HS CODE 300290, 2020–2024 (USD)

FIGURE 38 BOTULINUM TOXINS MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 39 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY TYPE

FIGURE 40 KEY BUYING CRITERIA OF BOTULINUM TOXINS, BY END USER

FIGURE 41 KEY AI USE CASES IN BOTULINUM TOXINS MARKET

FIGURE 42 NORTH AMERICA: BOTULINUM TOXINS MARKET SNAPSHOT

FIGURE 43 ASIA PACIFIC: BOTULINUM TOXINS MARKET SNAPSHOT

FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN BOTULINUM TOXINS MARKET, 2020–2024 (USD MILLION)

FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BOTULINUM TOXINS MARKET (2024)

FIGURE 46 MARKET RANKING OF KEY PLAYERS IN BOTULINUM TOXINS MARKET (2024)

FIGURE 47 EV/EBITDA OF TOP THREE PLAYERS (2025)

FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP THREE PLAYERS (2025)

FIGURE 49 BOTULINUM TOXINS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 50 BOTULINUM TOXINS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 51 BOTULINUM TOXINS MARKET: COMPANY FOOTPRINT

FIGURE 52 BOTULINUM TOXIN MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT

FIGURE 54 IPSEN BIOPHARMACEUTICALS, INC.: COMPANY SNAPSHOT

FIGURE 55 GALDERMA: COMPANY SNAPSHOT

FIGURE 56 HUGEL, INC.: COMPANY SNAPSHOT

FIGURE 57 EVOLUS, INC.: COMPANY SNAPSHOT

FIGURE 58 MEDYTOX: COMPANY SNAPSHOT

FIGURE 59 SUPERNUS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

FIGURE 60 HUONS: COMPANY SNAPSHOT

FIGURE 61 EISAI CO., LTD.: COMPANY SNAPSHOT

I would like to order

Product name: Botulinum Toxins Market by Product (Botox, Dysport, Jeuveau, Myobloc), Application (Cosmetic (Wrinkle Removal, Contouring, Skin rejuvenation), Therapeutic (OAB, Migraine, Spasm, Pain)), Volume, End User (Clinics, Center), Region - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/B76D1274800BEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B76D1274800BEN.html>